Document is current
Any future updates will be listed below
-
Authors
Reiss, Allan L. https://orcid.org/0000-0002-1979-4942
Jo, Booil
Arbelaez, Ana Maria
Tsalikian, Eva
Buckingham, Bruce
Weinzimer, Stuart A. https://orcid.org/0000-0002-7768-5189
Fox, Larry A.
Cato, Allison
White, Neil H.
Tansey, Michael
Aye, Tandy
Tamborlane, William
Englert, Kimberly
Lum, John
Mazaika, Paul https://orcid.org/0000-0002-9464-6333
Foland-Ross, Lara
Marzelli, Matthew
Mauras, Nelly
,
Tong, Gabby
Shen, Hanyang
Li, Zetan
Kingman, Ryan
Levandoski, Lucy
Coffey, Julie
Bisbee, Rachel
Stephen, Amy
Weyman, Kate
Bird, Keisha
Ponthieux, Kimberly
Marrero, Juan
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (5R01-HD-078463)
- License Information
-
More Information
Article History
Received: 6 January 2022
Accepted: 26 July 2022
First Online: 30 August 2022
Competing interests
: N.M. had institutional device supply agreements from Medtronic for CGM and LifeScan for test strips for the study, research support from Novo Nordisk. B.B. had consultant agreements with Medtronic Diabetes, Novo Nordisk, Dexcom, ConvaTec, Lilly, and Tolerion; has provided expert testimony for Dexcom; and has research grants with Insulet, Tandem, Medtronic, and Beta Bionics. E.T. had institutional research grants with AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Grifols Therapeutics, Takeda, and Amgen. S.A.W. had consultant agreements with Zealand; institutional grant support from Abbott and Medtronic; and speaker honoraria from Abbott, Dexcom, and Insulet. L.A.F. had a device supply agreement with Dexcom. A.M.A. had a device supply agreement with Dexcom. M.T. had a data safety monitoring board agreement with Daiichi Sankyo. W.T. had consultant agreements with AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, and Sanofi and data safety monitoring board agreements with Eisai, MannKind, and Tolerion. K.E. had a consultant agreement with PicoLife Technology. J.L. received consulting fees, paid to his institution, from Animas Corporation, Bigfoot Biomedical, Tandem Diabetes Care, and Eli Lilly and Company. No other potential competing interests relevant to this article were reported.
